Search Results 611-620 of 18372 for alopecia
Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia. Patients with ...
Recovery from non-hematologic toxic effects of prior therapy to grade ≤ 1 (except alopecia) by NCI CTCAE Version 4.03. Adequate bone marrow (BM), renal ...
The primary objective of this study is to assess the effect of berubicin compared with lomustine on overall survival (OS) in adult patients with Glioblastoma ...
... alopecia and endocrinopathies from prior immunotherapy-based treatments that are well-controlled with hormone replacement. Patients who are receiving any ...
Learn how to tell apart these common conditions of the scalp, both of which cause inflamed, scaly skin.
52 (58%) women were diagnosed with polycystic ovary syndrome (PCOS). Women with APT were more likely to have male-pattern alopecia documented on physical ...
Relevant toxicities of prior therapies must have resolved, except for oxaliplatin-related neuropathy or alopecia. Anticipated life expectancy ≥6 months ...
Participants with type 1 diabetes, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible; ...
... alopecia or neuropathy); Adequate organ function as defined by the following criteria: Serum aspartate transaminase (AST; serum glutamic oxaloacetic ...
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!